Literature DB >> 29267878

Computational identification of micro-structural variations and their proteogenomic consequences in cancer.

Yen-Yi Lin1,2, Alexander Gawronski1, Faraz Hach1,2,3, Sujun Li4, Ibrahim Numanagic1, Iman Sarrafi1,2, Swati Mishra5, Andrew McPherson1, Colin C Collins2,3, Milan Radovich5, Haixu Tang4, S Cenk Sahinalp2,4.   

Abstract

Motivation: Rapid advancement in high throughput genome and transcriptome sequencing (HTS) and mass spectrometry (MS) technologies has enabled the acquisition of the genomic, transcriptomic and proteomic data from the same tissue sample. We introduce a computational framework, ProTIE, to integratively analyze all three types of omics data for a complete molecular profile of a tissue sample. Our framework features MiStrVar, a novel algorithmic method to identify micro structural variants (microSVs) on genomic HTS data. Coupled with deFuse, a popular gene fusion detection method we developed earlier, MiStrVar can accurately profile structurally aberrant transcripts in tumors. Given the breakpoints obtained by MiStrVar and deFuse, our framework can then identify all relevant peptides that span the breakpoint junctions and match them with unique proteomic signatures. Observing structural aberrations in all three types of omics data validates their presence in the tumor samples.
Results: We have applied our framework to all The Cancer Genome Atlas (TCGA) breast cancer Whole Genome Sequencing (WGS) and/or RNA-Seq datasets, spanning all four major subtypes, for which proteomics data from Clinical Proteomic Tumor Analysis Consortium (CPTAC) have been released. A recent study on this dataset focusing on SNVs has reported many that lead to novel peptides. Complementing and significantly broadening this study, we detected 244 novel peptides from 432 candidate genomic or transcriptomic sequence aberrations. Many of the fusions and microSVs we discovered have not been reported in the literature. Interestingly, the vast majority of these translated aberrations, fusions in particular, were private, demonstrating the extensive inter-genomic heterogeneity present in breast cancer. Many of these aberrations also have matching out-of-frame downstream peptides, potentially indicating novel protein sequence and structure. Availability and implementation: MiStrVar is available for download at https://bitbucket.org/compbio/mistrvar, and ProTIE is available at https://bitbucket.org/compbio/protie. Contact: cenksahi@indiana.edu. Supplementary information: Supplementary data are available at Bioinformatics online.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29267878      PMCID: PMC5946953          DOI: 10.1093/bioinformatics/btx807

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  42 in total

1.  An automated proteogenomic method uses mass spectrometry to reveal novel genes in Zea mays.

Authors:  Natalie E Castellana; Zhouxin Shen; Yupeng He; Justin W Walley; California Jack Cassidy; Steven P Briggs; Vineet Bafna
Journal:  Mol Cell Proteomics       Date:  2013-10-18       Impact factor: 5.911

2.  Comrad: detection of expressed rearrangements by integrated analysis of RNA-Seq and low coverage genome sequence data.

Authors:  Andrew McPherson; Chunxiao Wu; Iman Hajirasouliha; Fereydoun Hormozdiari; Faraz Hach; Anna Lapuk; Stanislav Volik; Sohrab Shah; Colin Collins; S Cenk Sahinalp
Journal:  Bioinformatics       Date:  2011-04-09       Impact factor: 6.937

3.  Proteogenomic database construction driven from large scale RNA-seq data.

Authors:  Sunghee Woo; Seong Won Cha; Gennifer Merrihew; Yupeng He; Natalie Castellana; Clark Guest; Michael MacCoss; Vineet Bafna
Journal:  J Proteome Res       Date:  2013-07-17       Impact factor: 4.466

Review 4.  Proteomic applications for the early detection of cancer.

Authors:  Julia D Wulfkuhle; Lance A Liotta; Emanuel F Petricoin
Journal:  Nat Rev Cancer       Date:  2003-04       Impact factor: 60.716

Review 5.  Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells.

Authors:  J L Fernandez-Luna
Journal:  Apoptosis       Date:  2000-10       Impact factor: 4.677

Review 6.  The impact of translocations and gene fusions on cancer causation.

Authors:  Felix Mitelman; Bertil Johansson; Fredrik Mertens
Journal:  Nat Rev Cancer       Date:  2007-03-15       Impact factor: 60.716

7.  nFuse: discovery of complex genomic rearrangements in cancer using high-throughput sequencing.

Authors:  Andrew McPherson; Chunxiao Wu; Alexander W Wyatt; Sohrab Shah; Colin Collins; S Cenk Sahinalp
Journal:  Genome Res       Date:  2012-06-28       Impact factor: 9.043

8.  Dissect: detection and characterization of novel structural alterations in transcribed sequences.

Authors:  Deniz Yorukoglu; Faraz Hach; Lucas Swanson; Colin C Collins; Inanc Birol; S Cenk Sahinalp
Journal:  Bioinformatics       Date:  2012-06-15       Impact factor: 6.937

9.  MS-GF+ makes progress towards a universal database search tool for proteomics.

Authors:  Sangtae Kim; Pavel A Pevzner
Journal:  Nat Commun       Date:  2014-10-31       Impact factor: 14.919

10.  Chimeras taking shape: potential functions of proteins encoded by chimeric RNA transcripts.

Authors:  Milana Frenkel-Morgenstern; Vincent Lacroix; Iakes Ezkurdia; Yishai Levin; Alexandra Gabashvili; Jaime Prilusky; Angela Del Pozo; Michael Tress; Rory Johnson; Roderic Guigo; Alfonso Valencia
Journal:  Genome Res       Date:  2012-05-15       Impact factor: 9.043

View more
  2 in total

1.  FusionPro, a Versatile Proteogenomic Tool for Identification of Novel Fusion Transcripts and Their Potential Translation Products in Cancer Cells.

Authors:  Chae-Yeon Kim; Keun Na; Saeram Park; Seul-Ki Jeong; Jin-Young Cho; Heon Shin; Min Jung Lee; Gyoonhee Han; Young-Ki Paik
Journal:  Mol Cell Proteomics       Date:  2019-06-17       Impact factor: 5.911

Review 2.  The pseudogenes of eukaryotic translation elongation factors (EEFs): Role in cancer and other human diseases.

Authors:  Luigi Cristiano
Journal:  Genes Dis       Date:  2021-04-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.